Home > Events > Séminaires

Séminaire Chimie IBMM

Peptide coated nanoparticles, opportunities in bioimaging and medical applications

Dr David Paramelle (A*STAR Agency for Science, Technology and Research | Institute of Materials Research and Engineering, Singapore)

published on , updated on

Le Vendredi 06 octobre 2017 à 11h
UM Faculté de Pharmacie, Amphithéâtre D [attention, nouveau lieu !]

The design of thin peptide coatings to protect nanoparticles surface by forming highly stable peptide self-assembled monolayers[1] is an efficient way to break common limitations to the transfer of bare nanomaterials to biological and medical applications. The peptide coated nanoparticles are truly stable in biological environments for a long term and do not present any aspecific binding to live cells. This was demonstrated for instance on gold[2,3] and silver[4,5] nanoparticles and we recently used this strategy to developed biocompatible peptide coated ultra-small superparamagnetic iron nanoparticles for in vivo MRI. Furthermore, the peptide coating allows for stoichiometric control of the functionalization of nanoparticles by various means with targeting agents such as peptides or antibodies. We used functionalized peptide coated nanoparticles for long-term tracking of live-cells by photothermal microscopy[6] and for the preparation of hybrid nanomaterials in porous hollow protein cages.[7]

Here I will present our recent achievements and the opportunities of the peptide coated nanoparticles to develop hybrid nanomaterials, and performing targeting agents and contrast agents for bioimaging and medical applications.

References

1. E. Colangelo, Q. Chen, A.M. Davidson, D. Paramelle, M.B. Sullivan, M. Volk, R. Lévy, Computational and experimental investigation of the structure of peptide monolayers on gold nanoparticles. Langmuir 2017, 33, 438–449.
2. X. Chen, W.W. Qoutah, P. Free, J. Hobley, D.G. Fernig, D. Paramelle, Features of thiolated ligands promoting resistance to ligand exchange in self-assembled monolayers on gold nanoparticles. Aust. J. Chem. 2012, 65, 266.
3. L. Duchesne, D. Gentili, M. Comes-Franchini, D.G. Fernig, Robust ligand shells for biological applications of gold nanoparticles. Langmuir 2008, 24, 13572–13580.
4. P. Free, D. Paramelle, M. Bosman, J. Hobley, D.G. Fernig, Synthesis of silver nanoparticles with monovalently functionalized self-assembled monolayers. Aust. J. Chem. 2012, 65, 275.
5. D. Paramelle, A. Sadovoy, S. Gorelik, P. Free, J. Hobley, D.G. Fernig, A rapid method to estimate the concentration of citrate capped silver nanoparticles from UV-visible light spectra. Analyst 2014, 139, 4855.
6. D. Paramelle, D. Nieves, B. Brun, R. S. Kraut, D.G. Fernig, Targeting cell membrane lipid rafts by stoichiometric functionalization of gold nanoparticles with a sphingolipid-binding domain peptide. Adv. Healthc. Mater. 2015, 4, 911–917.
7. D. Paramelle, T. Peng, P. Free, D.G. Fernig, S. Lim, N. Tomczak, Specific internalisation of gold nanoparticles into engineered porous protein cages via affinity binding. PLoS One 2016, 11, e0162848.

Biosketch. le Dr David Paramelle a obtenu son doctorat en Ingénierie Moléculaire en 2009 sous la direction du Prof Jean Martinez et du Prof Gilles Subra à l’IBMM à la faculté de Pharmacie de Montpellier. Depuis 2010, il travaille en tant qu’Investigateur Principal à A*STAR - Agency for Science, Technology and Research, à l’Institute of Materials Research and Engineering à Singapour où il s’intéresse particulièrement à la préparation de mono-couches auto-assemblées composées de divers ligands et peptides courts pour le recouvrement et la biofonctionnalisation de surface de nanoparticules métalliques et oxides de métaux afin de leur fournir des propriétés compatibles in vitro et in vivo et de développer des sondes nanoparticulaires pour des applications en imagerie biologique et médicale. Il dirige plusieurs projets multidisciplinaires internationaux dont un projet qui a obtenu en 2014 un prix de la recherche, le Career Development Award du Joint Council Office de A*STAR. Ce projet en collaboration regroupe trois instituts de recherche à A*STAR, l’université de Liverpool et l’hôpital universitaire de Singapour, et a pour objectif de développer de nouveaux agents de contraste ciblant pour le diagnostic par imagerie par résonance magnétique et le traitement du cancer du sein.

Contact Local IBMM : Prof. Gilles Subra (DAPP)

Agenda

Ajouter un événement iCal